Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Guardant Health Inc Company Overview 4
Guardant Health Inc Company Snapshot 4
Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview 4
Guardant Health Inc – Pipeline Analysis Overview 7
Guardant Health Inc – Key Facts 7
Guardant Health Inc – Major Products and Services 8
Guardant Health Inc Pipeline Products by Development Stage 9
Guardant Health Inc Ongoing Clinical Trials by Trial Status 11
Guardant Health Inc Pipeline Products Overview 13
Anti-RSP03 Antibody Based Blood Test 13
Anti-RSP03 Antibody Based Blood Test Product Overview 13
Gene-Based Test – Lung Cancer 14
Gene-Based Test – Lung Cancer Product Overview 14
GUARDANT360 15
GUARDANT360 Product Overview 15
GUARDANT360 Clinical Trial 16
Guardant360 CDx Test – Tepotinib 18
Guardant360 CDx Test – Tepotinib Product Overview 18
Guardant360 Companion Diagnostic Assay – Glesatinib 19
Guardant360 Companion Diagnostic Assay – Glesatinib Product Overview 19
Guardant Health Inc – Key Competitors 20
Guardant Health Inc – Key Employees 21
Guardant Health Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Guardant Health Inc, Recent Developments 23
Jul 19, 2018: New Nature Medicine Study Demonstrates Ability of The Guardant360 Assay to Predict Patient Response to Immunotherapy in Advanced Gastric Cancer Patients 23
Jul 18, 2018: Foundation Medicine and Guardant Health Agree to Settle Patent Infringement Lawsuit 23
Jul 12, 2018: Guardant Health Appoints Leena Das-Young to Lead Efforts to Develop Liquid Biopsy Products for Early-Stage Cancer Applications 23
Jul 12, 2018: Guardant Health Announces Medicare Coverage for the Guardant360 Assay in Non-Small Cell Lung Cancer 24
May 23, 2018: Guardant Health to Present 29 Abstracts at ASCO Advancing the Science of Liquid Biopsy Across Multiple Indications and Applications 24
Apr 26, 2018: Guardant Health Publishes Extensive Validation of Guardant360 Assay Comprising Largest-Published Blood-Tissue Comparison 25
Apr 13, 2018: Guardant Health to Present Validation Data for the GuardantOMNI assay 25
Mar 19, 2018: Guardant Health Applauds Medicare For Final Decision Benefiting Advanced Cancer Patients 26
Mar 13, 2018: SCRUM-Japan GI-SCREEN Aims for Realizing of Cancer Precision Medicine Utilizing Liquid Biopsy by Analyzing Comprehensive Cancer Genome Alterations in Blood 26
Mar 12, 2018: Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of Lung Cancer Trial 27
Appendix 28
Methodology 28
About GlobalData 31
Contact Us 31
Disclaimer 31
Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview 4
Guardant Health Inc Pipeline Products by Equipment Type 5
Guardant Health Inc Pipeline Products by Indication 6
Guardant Health Inc Ongoing Clinical Trials by Trial Status 6
Guardant Health Inc, Key Facts 7
Guardant Health Inc, Major Products and Services 8
Guardant Health Inc Number of Pipeline Products by Development Stage 9
Guardant Health Inc Pipeline Products Summary by Development Stage 10
Guardant Health Inc Ongoing Clinical Trials by Trial Status 11
Guardant Health Inc Ongoing Clinical Trials Summary 12
Anti-RSP03 Antibody Based Blood Test - Product Status 13
Anti-RSP03 Antibody Based Blood Test - Product Description 13
Gene-Based Test - Lung Cancer - Product Status 14
Gene-Based Test - Lung Cancer - Product Description 14
GUARDANT360 - Product Status 15
GUARDANT360 - Product Description 15
GUARDANT360 - A Phase I Trial of Vemurafenib in Combination with Cetuximab and Irinotecan in Patients with BRAF V600 Mutant Advanced Solid Malignancies 16
GUARDANT360 - An Ambitious Multi-arm, Multi-site Umbrella Trial to Study Blood Test for Early Cancer Detection 16
GUARDANT360 - Circulating Free DNA Analysis in Gastrointestinal Cancer, Genitourinary Cancer, Rare Cancer 16
GUARDANT360 - Next Generation Personalized tX(Therapy) with Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial) 16
GUARDANT360 - Noninvasive versus Invasive Lung Evaluation 17
GUARDANT360 - Open-label, Phase II Study of Trastuzumab in Combination with Lapatinib (Cohort A) or Pertuzumab in Combination with Trastuzumab-emtansine (Cohort B) in Patients with HER2-positive Metastatic Colorectal Cancer: The HERACLES (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification)Trial 17
Guardant360 CDx Test - Tepotinib - Product Status 18
Guardant360 CDx Test - Tepotinib - Product Description 18
Guardant360 Companion Diagnostic Assay - Glesatinib - Product Status 19
Guardant360 Companion Diagnostic Assay - Glesatinib - Product Description 19
Guardant Health Inc, Key Employees 21
Glossary 30
List of Figures
Guardant Health Inc Pipeline Products by Equipment Type 5
Guardant Health Inc Pipeline Products by Development Stage 9
Guardant Health Inc Ongoing Clinical Trials by Trial Status 11